This capability enables the direct activation of cytotoxic lymphocytes, including CD8+ T cells (CTLs), natural killer cells, and NKT cells, positioning cDC1 as a central player in anti-tumor and antiviral immune responses, and thus a key target for enhancing vaccine efficacy [10]. This evidence concerns the gene CD8A and neoplasm.